SCHEDULE: OrbiMed Reduces MBX Biosciences Stake to 7.7%

OrbiMed Advisors and its affiliates have reduced their beneficial ownership in MBX Biosciences, Inc. to 7.7% due to share sales and an increase in outstanding shares.

Summary

• OrbiMed Advisors LLC and its affiliates (OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC) have filed an Amendment No. 2 to their Schedule 13D.
• The filing reports a decrease in their aggregate beneficial ownership of MBX Biosciences, Inc. common stock to 7.7% of the outstanding shares.
• This decrease is attributed to both an increase in the total number of MBX Biosciences shares outstanding and sales of shares by OrbiMed's affiliated funds.
• The total number of outstanding shares of MBX Biosciences, Inc. increased to 47,153,288, including 2,250,986 additional shares issued through an at-the-market offering program.
• OrbiMed Private Investments VII, LP (OPI VII) holds 2,958,000 shares (6.3%), and OrbiMed Genesis Master Fund, L.P. (Genesis) holds 679,887 shares (1.4%).
• Between December 26, 2025, and January 16, 2026, OPI VII and Genesis collectively sold numerous shares at prices ranging from $31.03 to $42.09 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal for MBX Biosciences, Inc. The reduction in stake by a prominent healthcare investor like OrbiMed, coupled with active share sales, suggests a potential shift in their investment strategy or a decision to take profits, which could weigh on investor sentiment.

Positives

• The issuer successfully completed an at-the-market offering, which provided additional capital.

Negatives

• A major institutional investor, OrbiMed, has reduced its stake in MBX Biosciences, Inc., which could be perceived negatively by the market.
• OrbiMed's affiliated funds actively sold shares over a period where the stock price was generally increasing, suggesting profit-taking.

Risks

• The Reporting Persons' stated intention to review their investment and potentially dispose of some or all of their shares in the future could lead to further selling pressure on the stock.

Future Outlook

The Reporting Persons intend to periodically review their investment in MBX Biosciences, Inc. based on various factors, including the Issuer's business, financial condition, market conditions, and other investment opportunities. They may acquire additional shares or dispose of existing shares in the future.

Management Comments

• No direct quotes or paraphrased statements from MBX Biosciences, Inc. management are included in this filing, as it is filed by the reporting persons (OrbiMed).

Industry Context

StockSavvy.ai notes that institutional investors like OrbiMed frequently adjust their positions in biotechnology companies based on clinical trial progress, regulatory milestones, and market valuations. A reduction in stake, while a routine disclosure, can sometimes signal a re-evaluation of the investment thesis or a strategic reallocation of capital within their portfolio, especially if the sales occur during periods of rising stock prices.

Comparison to Industry Standards

• Not applicable. This filing details a change in beneficial ownership by an institutional investor, not the operational or financial performance of MBX Biosciences, Inc. that would typically be compared to industry benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: The reduction in stake by a major institutional investor could lead to negative market sentiment and potentially downward pressure on the stock price. The at-the-market offering also diluted existing shareholders' percentage ownership.
• Company (MBX Biosciences): The at-the-market offering provided additional capital, which is generally positive for funding operations and growth.

Next Steps

• Reporting Persons will continue to review their investment in MBX Biosciences, Inc.
• Reporting Persons may acquire or dispose of additional shares in the future based on market conditions and other factors.
• The Issuer may be requested to file registration statements for OrbiMed's remaining registrable securities under the Investors' Rights Agreement.

Key Dates

Recommendation

While the reduction in stake by OrbiMed and their share sales could be perceived negatively, the filing itself is a disclosure of past actions and future intentions to review the investment. Without further information on MBX Biosciences' operational performance or specific reasons for OrbiMed's divestment beyond portfolio management, a 'hold' recommendation is prudent. Investors should monitor future filings and company performance for clearer directional signals.

Keywords

MBX Biosciences, OrbiMed Advisors, Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investor, Biotechnology, Healthcare Investment, Equity Stake, SEC Filing